Showing papers on "Doxorubicin published in 1975"

DNA complexing antibiotics: daunomycin, adriamycin and their derivatives.

Abstract: 9-Acetyl-4-methoxy-7,8,9,11-tetrahydroxy-6,7,9,11-tetrahydroxy-o-(3'-amino-2',3',6'-trideoxy-alpha-L-lyxohexopyranoside) (daunomycin, daunorubicin, NSC-82 131, Daunoblasin), 14-hydroxy-daunorubicin (adriamycin, doxorubicin, NSC-123 127, Adriblastin), dihydrodaunomycin, their aglycones and other related compounds represent the group of S. peucetius derived antibiotics. The biosynthetic glycosides as well as some semisynthetic analogues or derivatives form strong complexes with double stranded DNA, which can be understood in terms of the known intercalation model. A clear relationship is found between the complex forming ability and the biological activity of the different compounds. The structure and configuration of the sugar moiety appear of primary importance for the stabilization of the complex and, therefore, for action. A class of side chain derivatives, namely adriamycin 14-0-esters, looks promising. Different tissue distribution of such derivatives may result in new useful anticancer drugs.

Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.

Abstract: The two-drug combination of cyclophosphamide plus adriamycin was found to be therapeutically potentiating against four different C3H mammary tumor lines, the B16 melanoma, the Ridgway osteogenic sarcoma, and the P388 leukemia. The potentiation was not schedule dependent.

Adriamycin and Radiation: Synergistic Cardiotoxicity

Abstract: Excerpt To the editor: Severe cardiomyopathy with irreversible congestive heart failure from adriamycin is very rare if the dose is limited to below 500 to 550 mg/m2body surface area (1, 2). We hav...

Single and combination chemotherapy for primary murine bladder cancer

Abstract: Single and combination chemotherapy was evaluated for antitumor activity against N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT)-induced bladder carcinoma in syngeneic mice. Two hundred fifty C3H/He mice having ingested FANFT for 10 months were randomly divided into groups of 30, and the following regimens initiated: cyclophosphamide (Cy), cis-diam-minedichloroplatinum (cis-Pt-II), dactinomycin, adriamycin, Cy plus cis-Pt-II, Cy plus 5-fluorouracil, and Cy plus adriamycin. The drugs were administered for 3 weeks. Each regimen was capable of producing a significant reduction in the mean bladder weight (MBW) when compared to a groups not receiving therapy (108.3 mg). Adriamycin (MBW equal 69.5), dactinomycin (49.6), and cyclophosphamide (42.9) were the best single agents, but the greatest inhibition of tumor growth was achieved by the combination of cyclophosphamide with 5-fluorouracil (38.3) or adriamycin (37.3). These combination chemotherapeutic regimens were able to effect a significant reduction in the number of bladders with Stage C tumors. It is hoped that information gained from this new animal model which allows evaluation of many antitumor drugs within a relatively short period of time will lead to therapeutic trials in patients with locally advanced or metastatic bladder cancer.

Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

Abstract: The LD50 of intraperitoneally (ip) injected daunorubicin in nonleukemic mice (1.8 mg/kg, q4d times 3) can be increased several fold by the concomitant ip injection of ICRF-159. In addition, the survival of leukemic mice treated with daunorubicin and ICRF-159 on Days 1, 5, and 9 after ip inoculation of L1210 tumor cells was substantially greater than after treatment with either drug alone. This potentiation of survival with combination treatment usually occurred with doses of daunorubicin greater than the LD50 of daunorubicin alone. The LD50 of subcutaneously (sc) injected daunorubicin alone (14.0 mg/kg, q4d times 3) was not increased by concomitant ip treatment with ICRF-159. However, when leukemic mice were treated sc with daunorubicin and ip with ICRF-159 on Days 1, 5, and 9 after ip injection of L1210 leukemia cells, survival was greater than with treatment with either drug alone. The toxicity of ip injected adriamycin was not reduced by ICRF-159, but treatment of leukemic mice with this combination was more effective in prolonging survival than treatment with either drug alone. Combination treatment with daunorubicin plus ICRF-159 showed much less therapeutic enhancement against sc implanted L1210 leukemia than against the ip implanted tumor.

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.

Abstract: Adriamycin and cyclophosphamide are active agents in human and experimental tumours. Using the L1210 murine leukaemia, their effectiveness alone and in combination was studied. The combination is highly synergistic in this tumour, resulting in a greater than 50% survival rate when the agents used alone at optimal doses are not curative. DNA synthesis by tumour cells is substantially inhibited and the total ascitic population much reduced. In contrast, DNA synthesis in sensitive host tissues is less disturbed. There is no major difference in the pharmacology of the agents whether given alone or in combination. In very advanced disease the combination is no better than treatment with cyclophosphamide alone. The combination of adriamycin and melphalan in L1210 leukaemia also produces superior results to those obtained using either drug alone at its optimal dosage.